Dr. John M. Carethers to Deliver Second NCI CURE Distinguished Scholars Seminar
September 19, 2017, by CRCHD Staff
CRCHD is delighted to welcome John M. Carethers, MD, MACP, as the invited speaker for the second NCI Continuing Umbrella of Research Experiences (CURE) Distinguished Scholars Seminar.
Dr. Carethers is the C. Richard Boland Distinguished University Professor, John G. Searle Professor and Chair, and Internal Medicine Professor, Human Genetics at the University of Michigan. An expert in colorectal cancer disparities, he and his laboratory team study the development of colorectal neoplasms with a focus on DNA mismatch repair and colorectal cancer pathogenesis as it relates to genetics and clinical outcomes.
In his lecture, A Role for Inflammation-Induced DNA Mismatch Repair Deficits in Racial Outcomes from Advanced Colorectal Cancer, Dr. Carethers will present highlights from his current research in hereditary colon cancer, tumor progression, and colorectal cancer disparities.
This seminar will take place on October 5, 2017 from 1–2:30 PM ET at the NCI Shady Grove in TE406. For those unable to attend in person, a webinar option is available. Webinar attendees should register in advance.
The CURE Distinguished Scholars Seminar Series was launched earlier this year as part of the 21 years of the CURE program celebration. This semiannual, scientific seminar series aims to recognize CURE scholars who have made seminal contributions to the fields of cancer and cancer health disparities research, and are role models and mentors for other scientists from backgrounds underrepresented in cancer research.
Next year, CRCHD will host former CURE scholar, Levi Garraway, MD, PhD, who will present his research on the molecular and genomic characterization of human solid tumors. Dr. Garraway is Senior Vice President of Global Oncology at the Eli Lilly and Company, and was previously at the Harvard Medical School, Dana-Farber Cancer Institute, and the Broad Institute.
The CURE program supports underrepresented individuals across the academic continuum — beginning in middle school and continuing to cancer research independence — through a pipeline of research funding opportunities.